Faslg (Fas ligand) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: Faslg (Fas ligand) Rattus norvegicus
Analyze
Symbol: Faslg
Name: Fas ligand
RGD ID: 3880
Description: Enables death receptor binding activity and tumor necrosis factor receptor binding activity. Involved in several processes, including cellular response to type II interferon; endosomal lumen acidification; and intracellular chloride ion homeostasis. Located in caveola and perinuclear region of cytoplasm. Used to study brain glioma; substance-related disorder; and type 1 diabetes mellitus. Biomarker of several diseases, including artery disease (multiple); gastric ulcer; graft-versus-host disease; liver disease (multiple); and ulcerative colitis. Human ortholog(s) of this gene implicated in several diseases, including cholangiocarcinoma; chronic myeloid leukemia; diabetes mellitus (multiple); pancreatic cancer (multiple); and pre-eclampsia (multiple). Orthologous to human FASLG (Fas ligand); PARTICIPATES IN extrinsic apoptotic pathway; FasL mediated signaling pathway; interleukin-12 signaling pathway; INTERACTS WITH (R,R,R)-alpha-tocopherol; (S)-nicotine; 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: apoptosis (APO-1) antigen ligand 1 (Fas antigen ligand); Apt1Lg1; CD95 ligand; CD95-L; CD95L protein; Fas antigen ligand; Fas ligand (TNF superfamily, member 6); Fasl; Tnfsf6; Tnlg1a; Tumor necrosis factor (ligand) superfamily member 6 (apoptosis (APO-1) antigen ligand 1) (Fas antigen ligand); tumor necrosis factor (ligand) superfamily, member 6; Tumor necrosis factor (ligand) superfamily, member 6 (apoptosis (APO-1) antigen ligand 1) (Fas antigen ligand); tumor necrosis factor ligand 1a; tumor necrosis factor ligand superfamily member 6
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Black Rat
Alliance Orthologs
More Info more info ...
Allele / Splice: FaslgTn(sb-T2/Bart3)2.325Mcwi
Genetic Models: F344-FaslgTn(sb-T2/Bart3)2.325Mcwi
Latest Assembly: GRCr8 - GRCr8 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81376,680,885 - 76,706,042 (-)NCBIGRCr8GRCr8GRCr8
GRCr8 Ensembl1376,688,243 - 76,695,503 (-)EnsemblGRCr8
mRatBN7.21374,151,519 - 74,172,760 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1374,154,954 - 74,162,215 (-)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx1376,724,620 - 76,731,883 (-)NCBIUTH_Rnor_SHR_UtxUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01378,031,667 - 78,038,929 (-)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0UTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01375,291,523 - 75,298,787 (-)NCBIUTH_Rnor_WKY_Bbb_1.0UTH_Rnor_WKY_Bbb_1.0
Rnor_6.01379,696,811 - 79,717,581 (-)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1379,698,445 - 79,705,705 (-)Ensemblrn6Rnor6.0
Rnor_5.01384,590,119 - 84,605,900 (-)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.41377,472,950 - 77,480,210 (-)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera1373,908,438 - 73,915,703 (-)NCBICelera
RGSC_v3.11377,487,137 - 77,494,398 (-)NCBI
Cytogenetic Map13q22NCBI
JBrowse:




Disease Annotations     Click to see Annotation Detail View
abdominal aortic aneurysm  (IEP)
Acute Experimental Pancreatitis  (ISO)
Acute Hepatitis  (IEP,ISO)
Acute Liver Failure  (ISO)
Acute Lung Injury  (ISO)
aplastic anemia  (ISO)
arteriosclerosis  (ISO)
atherosclerosis  (ISO)
autoimmune hepatitis  (ISO)
autoimmune lymphoproliferative syndrome  (ISO,ISS)
Autoimmune Lymphoproliferative Syndrome, Type IB  (ISO)
biliary tract benign neoplasm  (ISO)
brain glioma  (IDA)
brain ischemia  (IEP)
Breast Neoplasms  (ISO)
cardiomyopathy  (ISO)
Cardiotoxicity  (ISO)
carotid artery disease  (ISO)
carotid stenosis  (ISO)
cervix uteri carcinoma in situ  (ISO)
cholangiocarcinoma  (ISO)
chronic myeloid leukemia  (ISO)
chronic obstructive pulmonary disease  (IEP)
clonorchiasis  (IEP)
congestive heart failure  (IEP)
cystic fibrosis  (ISO)
diabetic angiopathy  (ISO)
Diabetic Nephropathies  (ISO)
dilated cardiomyopathy  (ISO)
drug allergy  (ISO)
Esophageal Neoplasms  (ISO)
Experimental Allergic Asthma  (IEP)
Experimental Arthritis  (IMP)
Experimental Autoimmune Encephalomyelitis  (ISO)
Experimental Diabetes Mellitus  (IEP)
familial combined hyperlipidemia  (ISO)
Fetal Growth Retardation  (ISO)
Gallbladder Neoplasms  (ISO)
gastric ulcer  (IEP)
graft-versus-host disease  (IEP,ISO)
HELLP syndrome  (IEP,ISO)
hepatitis  (ISO)
hepatitis B  (ISO)
hepatocellular carcinoma  (ISO)
Huntington's disease  (ISO)
Hypothermia  (IEP)
idiopathic pulmonary fibrosis  (ISO)
immunodeficiency 98  (ISO)
infectious mononucleosis  (ISO)
Intestinal Reperfusion Injury  (IEP)
intrahepatic cholangiocarcinoma  (ISO)
invasive lobular carcinoma  (ISO)
Kidney Reperfusion Injury  (IEP)
leiomyoma  (ISO)
limited scleroderma  (ISO)
liver disease  (IEP)
Liver Injury  (ISO)
Liver Reperfusion Injury  (IMP)
lung cancer  (ISO)
Lung Injury  (IEP)
Lung Neoplasms  (ISO)
lung non-small cell carcinoma  (ISO)
melanoma  (ISO)
multiple myeloma  (ISO)
multiple sclerosis  (ISO)
myelodysplastic syndrome  (ISO)
Necrosis  (ISO)
Neoplasm Metastasis  (ISO)
Oxygen-Induced Retinopathy  (ISO)
pancreatic cancer  (ISO)
pancreatic ductal carcinoma  (ISO)
Parkinson's disease  (IEP,ISO)
pre-eclampsia  (ISO)
Prostatic Neoplasms  (ISO)
renal cell carcinoma  (ISO)
rheumatoid arthritis  (ISO)
seminoma  (ISO)
Sepsis  (IEP)
Spinal Cord Compression  (ISO)
substance-related disorder  (IDA)
testicular disease  (ISO)
transitional cell carcinoma  (ISO)
Transplant Rejection  (IEP)
type 1 diabetes mellitus  (IDA,ISO,ISS)
type 2 diabetes mellitus  (ISO)
ulcerative colitis  (IEP)
urinary bladder cancer  (ISO)
Uterine Cervical Neoplasms  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(E)-roxithromycin  (ISO)
(R)-adrenaline  (ISO)
(R,R,R)-alpha-tocopherol  (EXP)
(S)-naringenin  (ISO)
(S)-nicotine  (EXP,ISO)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (EXP,ISO)
1,2-dichloroethane  (ISO)
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  (ISO)
17beta-estradiol  (EXP,ISO)
17beta-estradiol 3-benzoate  (EXP)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4,6-trinitrobenzenesulfonic acid  (ISO)
2,4-D  (EXP,ISO)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (ISO)
2,5-hexanedione  (EXP)
2,6-dichloroindophenol  (ISO)
2-naphthylamine  (ISO)
3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (EXP)
3-chloropropane-1,2-diol  (ISO)
4'-epidoxorubicin  (EXP)
4,4'-diaminodiphenylmethane  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-hydroperoxycyclophosphamide  (ISO)
4-nitro-m-cresol  (ISO)
4-nonylphenol  (EXP)
5-azacytidine  (ISO)
5-fluorouracil  (ISO)
8-Br-cAMP  (ISO)
9-Methoxycamptothecin  (ISO)
[6]-Shogaol  (ISO)
acetamide  (EXP)
acetylsalicylic acid  (EXP)
acrolein  (EXP,ISO)
acrylamide  (EXP)
adenosine  (ISO)
aldehydo-D-glucose  (ISO)
aldosterone  (EXP)
all-trans-acitretin  (ISO)
all-trans-retinoic acid  (ISO)
Aloe emodin  (ISO)
alpha-naphthoflavone  (ISO)
ammonium chloride  (EXP)
amphibole asbestos  (ISO)
andrographolide  (ISO)
androst-4-ene-3,17-dione  (EXP)
anthocyanin  (EXP)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
antirheumatic drug  (ISO)
arachidonic acid  (ISO)
arecoline  (EXP)
aristolochic acid A  (EXP,ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenous acid  (ISO)
asbestos  (ISO)
atenolol  (ISO)
atorvastatin calcium  (EXP,ISO)
atrazine  (ISO)
Azoxymethane  (EXP,ISO)
bafilomycin A1  (EXP,ISO)
benazepril  (EXP)
benzene-1,2,4-triol  (ISO)
benzo[a]pyrene  (ISO)
Benzo[k]fluoranthene  (ISO)
berberine  (ISO)
beta-hexachlorocyclohexane  (EXP)
beta-naphthoflavone  (ISO)
beta-patchoulene  (EXP)
bezafibrate  (ISO)
bifenthrin  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bisphenol A  (EXP,ISO)
bleomycin A2  (ISO)
bortezomib  (ISO)
bufalin  (ISO)
busulfan  (ISO)
Butylbenzyl phthalate  (ISO)
cadmium atom  (EXP,ISO)
cadmium dichloride  (EXP,ISO)
Calcimycin  (ISO)
calcitriol  (EXP)
calcium atom  (ISO)
calcium(0)  (ISO)
candesartan  (EXP)
cannabidiol  (ISO)
capsaicin  (EXP)
capsazepine  (ISO)
carbachol  (ISO)
carbamazepine  (ISO)
carbon disulfide  (EXP)
carbon nanotube  (ISO)
carvedilol  (ISO)
casticin  (ISO)
catechol  (ISO)
CCCP  (EXP)
celastrol  (ISO)
celecoxib  (EXP)
chloramphenicol  (ISO)
chloroquine  (ISO)
chlorpyrifos  (ISO)
cholesterol  (EXP)
choline  (ISO)
chrysazin  (ISO)
chrysin  (EXP)
cisplatin  (EXP,ISO)
clothianidin  (ISO)
clozapine  (ISO)
cobalt atom  (ISO)
cobalt dichloride  (ISO)
coenzyme Q10  (EXP)
coformycin  (ISO)
copper(II) sulfate  (ISO)
curcumin  (EXP,ISO)
cycloheximide  (EXP,ISO)
cyclophosphamide  (ISO)
cyclosporin A  (EXP,ISO)
D-glucose  (ISO)
daunorubicin  (EXP)
DDE  (EXP)
DDT  (EXP)
deoxynivalenol  (ISO)
dexamethasone  (EXP,ISO)
diarsenic trioxide  (ISO)
diazinon  (ISO)
dibenziodolium  (EXP)
dibromoacetic acid  (ISO)
Dibutyl phosphate  (ISO)
dichlorvos  (ISO)
diclofenac  (ISO)
diethylstilbestrol  (EXP,ISO)
dihydroxyacetone  (ISO)
Dimethyl phthalate  (EXP)
dimethyl sulfoxide  (EXP)
dimethylarsinic acid  (EXP,ISO)
dioscin  (ISO)
dioxygen  (ISO)
disulfiram  (ISO)
doxazosin  (ISO)
doxorubicin  (EXP,ISO)
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor  (ISO)
elemental selenium  (ISO)
emodin  (ISO)
enalapril  (EXP)
esculetin  (ISO)
ethanol  (EXP,ISO)
etoposide  (ISO)
Evodiamine  (ISO)
fenpropathrin  (EXP)
fenvalerate  (EXP)
fisetin  (ISO)
flavanone  (ISO)
flavonoids  (EXP,ISO)
flucloxacillin  (ISO)
flutamide  (EXP)
formaldehyde  (EXP)
fructose  (ISO)
fulvestrant  (ISO)
furan  (EXP)
furosemide  (EXP)
Fusarenone X  (ISO)
gallic acid  (ISO)
gamma-hexachlorocyclohexane  (EXP)
gefitinib  (ISO)
Geniposide pentaacetate  (EXP)
genistein  (ISO)
glucose  (ISO)
glutathione  (ISO)
glycidol  (EXP)
glyphosate  (ISO)
GSK-J4  (ISO)
hexachlorobenzene  (EXP)
hydralazine  (EXP,ISO)
hydrogen peroxide  (EXP,ISO)
hydroquinone  (ISO)
hydroquinone O-beta-D-glucopyranoside  (ISO)
hydroxyurea  (ISO)
hyperforin  (ISO)
idelalisib  (ISO)
ifosfamide  (ISO)
inosine  (ISO)
ionomycin  (ISO)
irinotecan  (ISO)
isoflurane  (EXP)
isoprenaline  (EXP)
L-methionine  (ISO)
lansoprazole  (EXP)
lenalidomide  (ISO)
linderalactone  (ISO)
linsidomine  (ISO)
lipopolysaccharide  (EXP,ISO)
losartan  (EXP)
lovastatin  (ISO)
lupulone  (ISO)
LY294002  (ISO)
lycopene  (ISO)
magnesium oxide  (ISO)
manganese(II) chloride  (EXP)
manumycin A  (ISO)
masoprocol  (EXP,ISO)
medroxyprogesterone acetate  (ISO)
melatonin  (EXP,ISO)
methamphetamine  (EXP)
methotrexate  (EXP)
methoxychlor  (EXP)
methylarsonic acid  (EXP)
mifepristone  (ISO)
mitogen  (ISO)
mitomycin C  (ISO)
Mitoquinone  (EXP)
Mitotane  (EXP)
MK 571  (ISO)
mono(2-ethylhexyl) phthalate  (ISO)
monocrotaline  (ISO)
monosodium L-glutamate  (ISO)
morin  (ISO)
morphine  (ISO)
Myrtucommulone A  (ISO)
N-acetyl-L-cysteine  (EXP,ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (ISO)
N-methyl-N'-nitro-N-nitrosoguanidine  (ISO)
N-nitrosodiethylamine  (EXP)
NADP zwitterion  (ISO)
NADP(+)  (ISO)
naproxen  (EXP)
nickel atom  (ISO)
nicotinamide  (ISO)
nicotine  (EXP,ISO)
nicotinic acid-adenine dinucleotide phosphate  (ISO)
nimustine  (ISO)
nitric oxide  (ISO)
nitrobenzene  (ISO)
nocodazole  (ISO)
Nodularin  (ISO)
NS-398  (ISO)
Nutlin-3  (ISO)
ochratoxin A  (EXP)
octreotide  (ISO)
ouabain  (ISO)
ozone  (ISO)
p-menthan-3-ol  (ISO)
paclitaxel  (ISO)
paracetamol  (ISO)
paraquat  (ISO)
parthenolide  (ISO)
pentobarbital  (EXP)
pepstatin A  (EXP)
perfluorooctane-1-sulfonic acid  (ISO)
phenethyl caffeate  (ISO)
phenobarbital  (ISO)
phenol  (ISO)
phenytoin  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
phylloquinone  (ISO)
platycodin D  (ISO)
probenecid  (ISO)
propanal  (ISO)
prostaglandin E2  (ISO)
pterostilbene  (ISO)
puerarin  (ISO)
pyrethrins  (ISO)
pyruvic acid  (ISO)
quercetin  (EXP,ISO)
reactive oxygen species  (ISO)
rebaudioside A  (ISO)
regorafenib  (ISO)
resveratrol  (ISO)
rifampicin  (ISO)
ritonavir  (ISO)
Roridin A  (ISO)
ryanodine  (ISO)
S-allylcysteine  (ISO)
S-butyl-DL-homocysteine (S,R)-sulfoximine  (ISO)
S-nitroso-N-acetyl-D-penicillamine  (ISO)
S-nitrosoglutathione  (ISO)
sanguinarine  (ISO)
SB 203580  (ISO)
Se-methyl-L-selenocysteine  (ISO)
Se-methylselenocysteine  (ISO)
selenium atom  (ISO)
silicon dioxide  (ISO)
sirolimus  (ISO)
sodium arsenite  (EXP,ISO)
sodium dichromate  (ISO)
sodium fluoride  (ISO)
sorafenib  (ISO)
steviol  (ISO)
stevioside  (ISO)
streptozocin  (EXP)
sulforaphane  (ISO)
sumatriptan  (EXP)
swainsonine  (EXP)
tacrolimus hydrate  (ISO)
tamoxifen  (EXP,ISO)
telmisartan  (EXP,ISO)
temozolomide  (ISO)
testosterone  (EXP,ISO)
tetrachloromethane  (EXP,ISO)
tetrazolium violet  (ISO)
thalidomide  (ISO)
Theaflavin 3,3'-digallate  (ISO)
thioacetamide  (EXP)
thiosalicylic acid  (EXP)
thymidine  (ISO)
Tributyltin oxide  (ISO)
trichloroethene  (EXP)
trimethylarsine oxide  (EXP)
trimethyltin  (ISO)
triphenyl phosphate  (ISO)
Triptolide  (ISO)
triptonide  (ISO)
troglitazone  (ISO)
Tungsten carbide  (ISO)
uranium atom  (EXP)
uridine  (ISO)
usnic acid  (ISO)
valsartan  (EXP)
vanadyl sulfate  (ISO)
vanillin  (EXP)
vemurafenib  (ISO)
vincaleukoblastine  (ISO)
vincristine  (ISO)
vinorelbine  (ISO)
vorinostat  (ISO)
VX nerve agent  (ISO)
wortmannin  (ISO)
Y-27632  (ISO)
zearalenone  (EXP)
zidovudine  (EXP,ISO)
zinc atom  (ISO)
zinc protoporphyrin  (ISO)
zinc(0)  (ISO)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function

Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype
References

References - curated
# Reference Title Reference Citation
1. Lethal hepatitis after gene transfer of IL-4 in the liver is independent of immune responses and dependent on apoptosis of hepatocytes: a rodent model of IL-4-induced hepatitis. null
2. Inhibition of Fas-mediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury. Ackery A, etal., J Neurotrauma. 2006 May;23(5):604-16.
3. Lung injury after ischemia-reperfusion of small intestine in rats involves apoptosis of type II alveolar epithelial cells mediated by TNF-alpha and activation of Bid pathway. An S, etal., Apoptosis. 2007 Nov;12(11):1989-2001. doi: 10.1007/s10495-007-0125-1.
4. Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. Ares-Carrasco S, etal., Am J Physiol Heart Circ Physiol. 2009 Oct 9.
5. Expression of Fas and Fas ligand in human testicular germ cell tumours. Baldini E, etal., Int J Androl. 2007 Oct 3;.
6. Binding of the intracellular Fas ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localization of FasL. Baum W, etal., J Biol Chem. 2005 Dec 2;280(48):40012-24. Epub 2005 Oct 4.
7. Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread. Bebenek M, etal., Anticancer Res. 2007 Jan-Feb;27(1A):215-8.
8. Fas ligand expression in the organ of Corti. Bodmer D, etal., Audiol Neurootol 2003 Sep-Oct;8(5):243-9.
9. Cross-Talk between Fas/Fas ligand system and nitric oxide in the pathway subserving granulosa cell apoptosis: a possible regulatory mechanism for ovarian follicle atresia. Chen Q, etal., Endocrinology 2005 Feb;146(2):808-15. Epub 2004 Nov 4.
10. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Chopin D, etal., Am J Pathol. 2003 Apr;162(4):1139-49.
11. Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance. Cosson E, etal., Diabetes Metab. 2005 Feb;31(1):47-54.
12. FasL, Fas, and death-inducing signaling complex (DISC) proteins are recruited to membrane rafts after spinal cord injury. Davis AR, etal., J Neurotrauma. 2007 May;24(5):823-34.
13. Corticotropin-releasing hormone induces Fas ligand production and apoptosis in PC12 cells via activation of p38 mitogen-activated protein kinase. Dermitzaki E, etal., J Biol Chem 2002 Apr 5;277(14):12280-7. Epub 2002 Jan 14.
14. Fas and Fas ligand expression in cystic fibrosis airway epithelium. Durieu I, etal., Thorax. 1999 Dec;54(12):1093-8.
15. Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia. Edathara PM, etal., Tumour Biol. 2015 Nov 13.
16. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. Elnemr A, etal., Int J Oncol. 2001 Jan;18(1):33-9.
17. Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease. Enjoji M, etal., Liver Int. 2004 Aug;24(4):330-4.
18. H(2)O(2) induces upregulation of Fas and Fas ligand expression in NGF-differentiated PC12 cells: modulation by cAMP. Facchinetti F, etal., J Neurosci Res 2002 Jul 15;69(2):178-88.
19. IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. Faggioni R, etal., J Immunol. 2001 Nov 15;167(10):5913-20.
20. Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Ferrer I, etal., Neuropathol Appl Neurobiol. 2000 Oct;26(5):424-33.
21. apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding of a positive association for a polymorphism in the TNFRSF6 gene. Feuk L, etal., Hum Genet 2000 Oct;107(4):391-6.
22. A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. Franke DD, etal., Mol Immunol. 2007 Apr;44(11):2884-92. Epub 2007 Feb 26.
23. Fas/FasL play a central role in pancreatitis-induced hepatocyte apoptosis. Gallagher SF, etal., J Gastrointest Surg. 2005 Apr;9(4):467-74; discussion 474-5. doi: 10.1016/j.gassur.2004.12.008.
24. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
25. Dysregulation of the Fas/FasL system in an experimental animal model of HELLP syndrome. Gibbens J, etal., Pregnancy Hypertens. 2017 Apr;8:26-30. doi: 10.1016/j.preghy.2017.02.004. Epub 2017 Feb 24.
26. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Gratas C, etal., Cancer Res. 1998 May 15;58(10):2057-62.
27. Peripheral blood cytotoxic lymphocyte gene transcript levels differ in patients with long-term type 1 diabetes compared to normal controls. Han D, etal., Cell Transplant. 2005;14(6):403-9.
28. Insulitis in human type 1 diabetes. Hanafusa T and Imagawa A, Ann N Y Acad Sci. 2008 Dec;1150:297-9.
29. T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis. Hao Z, etal., J Exp Med. 2004 May 17;199(10):1355-65.
30. Immunohistochemical detection of CD 95 (Fas) & Fas ligand (Fas-L) in plasma cells of multiple myeloma and its correlation with survival. Hekimgil M, etal., Leuk Lymphoma. 2006 Feb;47(2):271-80.
31. Pentoxifylline attenuates cytokine stress and Fas system in syngeneic liver proteins induced experimental autoimmune hepatitis. Hendawy N, Biomed Pharmacother. 2017 Aug;92:316-323. doi: 10.1016/j.biopha.2017.05.084. Epub 2017 May 25.
32. Fas/Fas-ligand expressions in peripheral-blood mononuclear cells of patients with myelodysplastic syndromes. Hirano T, etal., Res Commun Mol Pathol Pharmacol. 2003;113-114:315-28.
33. Analysis of the Fas system and Bcl-2 in rat liver allograft rejection. Hiroyasu S, etal., J Surg Res. 1999 Jun 15;84(2):204-11. doi: 10.1006/jsre.1999.5644.
34. Expression of Fas and Fas ligand reflects the biological characteristics but not the status of apoptosis of intrahepatic cholangiocellular carcinoma. Ito Y, etal., Int J Mol Med. 2000 Nov;6(5):581-6.
35. Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Jayanthi S, etal., Proc Natl Acad Sci U S A 2005 Jan 18;102(3):868-73. Epub 2005 Jan 11.
36. Ischemic Postconditioning Protects Against Intestinal Ischemia/Reperfusion Injury via the HIF-1a/miR-21 Axis. Jia Z, etal., Sci Rep. 2017 Nov 23;7(1):16190. doi: 10.1038/s41598-017-16366-6.
37. Genetic kininogen deficiency contributes to aortic aneurysm formation but not to atherosclerosis. Kaschina E, etal., Physiol Genomics 2004 Sep 16;19(1):41-9. Epub 2004 Jul 06.
38. Expression of proliferative and preapoptotic molecules in human myometrium and leiomyoma throughout the menstrual cycle. Kayisli UA, etal., Reprod Sci. 2007 Oct;14(7):678-86.
39. The apoptotic effects of oxidative stress and antiapoptotic effects of caspase inhibitors on rat notochordal cells. Kim KW, etal., Spine (Phila Pa 1976). 2007 Oct 15;32(22):2443-8.
40. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Kitagawa M, etal., Leukemia. 1998 Apr;12(4):486-92.
41. Hepatocellular apoptosis is mediated by TNFalpha-dependent Fas/FasLigand cytotoxicity in a murine model of acute liver failure. Kuhla A, etal., Apoptosis. 2008 Dec;13(12):1427-38. doi: 10.1007/s10495-008-0269-7.
42. Fas ligand is enriched in the caveolae membrane domains of thymic epithelial cells. Lalor D, etal., Cell Immunol 2004 Jul;230(1):10-6.
43. Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation. Laskowska M, etal., Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):155-9. Epub 2005 Sep 19.
44. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Le-Niculescu H, etal., Mol Cell Biol. 1999 Jan;19(1):751-63.
45. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD. Lee S, etal., Bone Marrow Transplant. 1997 Nov;20(10):883-8.
46. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Lee SH, etal., Hum Pathol. 2001 Mar;32(3):250-6. doi: 10.1053/hupa.2001.22769.
47. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Li C, etal., Pharmacogenet Genomics. 2006 Apr;16(4):245-51.
48. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Li C, etal., Pharmacogenet Genomics. 2006 Apr;16(4):253-63.
49. Distinct overexpression of Fas ligand on T lymphocytes in aplastic anemia. Li W, etal., Cell Mol Immunol. 2004 Apr;1(2):142-7.
50. Prophylactic efficacy of patchoulene epoxide against ethanol-induced gastric ulcer in rats: Influence on oxidative stress, inflammation and apoptosis. Liang J, etal., Chem Biol Interact. 2018 Mar 1;283:30-37. doi: 10.1016/j.cbi.2018.01.014. Epub 2018 Jan 12.
51. FasL shedding is reduced by hypothermia in experimental stroke. Liu L, etal., J Neurochem. 2008 Jul;106(2):541-50. Epub 2008 Apr 12.
52. Effects of apigenin on the expression levels of B-cell lymphoma-2, Fas and Fas ligand in renal ischemia-reperfusion injury in rats. Liu Y, etal., Exp Ther Med. 2017 Dec;14(6):5345-5354. doi: 10.3892/etm.2017.5241. Epub 2017 Oct 2.
53. NFAT-1 hyper-activation by methionine enkephalin (MENK) significantly induces cell apoptosis of rats C6 glioma in vivo and in vitro. Lu WC, etal., Int Immunopharmacol. 2018 Mar;56:1-8. doi: 10.1016/j.intimp.2018.01.005. Epub 2018 Jan 9.
54. NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Martin-Ventura JL, etal., Stroke. 2004 Feb;35(2):458-63. Epub 2004 Jan 22.
55. Fas-ligand is stored in secretory lysosomes of ocular barrier epithelia and released with microvesicles. McKechnie NM, etal., Exp Eye Res. 2006 Aug;83(2):304-14. Epub 2006 Mar 24.
56. Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. Minana JB, etal., Hepatology. 2002 May;35(5):1205-14.
57. Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure. Mita A, etal., Am J Gastroenterol. 2005 Nov;100(11):2551-9. doi: 10.1111/j.1572-0241.2005.00265.x.
58. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Mizutani Y, etal., Cancer Biother Radiopharm. 2002 Oct;17(5):563-7.
59. The role of the Fas/Fas ligand system in estrogen-induced thymic alteration. Mor G, etal., Am J Reprod Immunol. 2001 Oct;46(4):298-307.
60. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. Mullauer L, etal., J Pathol. 2000 Jan;190(1):20-30.
61. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma. Murakami M, etal., Oncol Rep. 2004 Jun;11(6):1183-6.
62. Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation. Müschen M, etal., Gastroenterology. 1999 Mar;116(3):666-77. doi: 10.1016/s0016-5085(99)70189-7.
63. Blockade of the Fas/Fas ligand interaction suppresses hepatocyte apoptosis in ischemia-reperfusion rat liver. Nakajima H, etal., Apoptosis. 2008 Aug;13(8):1013-21. doi: 10.1007/s10495-008-0234-5.
64. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
65. Association of a microsatellite in FASL to type II diabetes and of the FAS-670G>A genotype to insulin resistance. Nolsoe RL, etal., Genes Immun. 2006 Jun;7(4):316-21. Epub 2006 May 4.
66. Fas ligand expression in human pancreatic cancer. Ohta T, etal., Oncol Rep. 2004 Oct;12(4):749-54.
67. Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis. Okuda Y, etal., Biochem Biophys Res Commun. 2000 Aug 18;275(1):164-8.
68. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
69. Expression of FasL and its interaction with Fas are mediated by c-Jun N-terminal kinase (JNK) pathway in 6-OHDA-induced rat model of Parkinson disease. Pan J, etal., Neurosci Lett. 2007 Nov 27;428(2-3):82-7. Epub 2007 Sep 25.
70. Protein kinase C-zeta (PKC-zeta) regulates Kupffer cell apoptosis during experimental sepsis. Peng Y, etal., J Gastrointest Surg. 2007 Dec;11(12):1712-21. Epub 2007 Sep 25.
71. Nuclear factor-kappaB mediates Kupffer cell apoptosis through transcriptional activation of Fas/FasL. Peng Y, etal., J Surg Res. 2006 Jan;130(1):58-65. Epub 2005 Sep 8.
72. Fas and Fas ligand expression in pancreatic adenocarcinoma. Pernick NL, etal., Pancreas. 2002 Oct;25(3):e36-41.
73. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
74. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
75. FAS A-670G and Fas ligand IVS2nt A 124G polymorphisms are significantly increased in women with pre-eclampsia and may contribute to HELLP syndrome: a case-controlled study. Raguema N, etal., BJOG. 2018 Dec;125(13):1758-1764. doi: 10.1111/1471-0528.15412. Epub 2018 Sep 3.
76. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease. Ramirez-Montagut T, etal., J Immunol. 2007 Aug 1;179(3):1669-80.
77. CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells. Reinehr R, etal., Gastroenterology. 2008 May;134(5):1494-506. Epub 2008 Feb 14.
78. Hyperosmolarity triggers CD95 membrane trafficking and sensitizes rat hepatocytes toward CD95L-induced apoptosis. Reinehr R, etal., Hepatology 2002 Sep;36(3):602-14.
79. Amplification of CD95 activation by caspase 8-induced endosomal acidification in rat hepatocytes. Reinehr R, etal., J Biol Chem. 2008 Jan 25;283(4):2211-22. Epub 2007 Nov 28.
80. GOA pipeline RGD automated data pipeline
81. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
82. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
83. Naringin attenuates liver damage in streptozotocin-induced diabetic rats. Rodríguez V, etal., Biomed Pharmacother. 2018 Sep;105:95-102. doi: 10.1016/j.biopha.2018.05.120. Epub 2018 May 28.
84. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Ryo K, etal., Am J Gastroenterol. 2000 Aug;95(8):2047-55. doi: 10.1111/j.1572-0241.2000.02268.x.
85. Association of human leukocyte antigen and T cell message with human papillomavirus 16-positive cervical neoplasia in Japanese women. Saito M, etal., Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1314-21. Epub 2007 Apr 13.
86. Regulation of Fas ligand expression by estrogen in normal ovary. Sapi E, etal., J Soc Gynecol Investig 2002 Jul-Aug;9(4):243-50.
87. Cellular expressions and serum concentrations of Fas ligand and Fas receptor in patients with infectious mononucleosis. Sato T, etal., Int J Hematol. 2000 Oct;72(3):329-36.
88. Fas ligand is frequently expressed in human pancreatic duct cell carcinoma. Satoh K, etal., Pancreas. 1999 Nov;19(4):339-45.
89. Liver receptor homolog-1 (NR5a2) regulates CD95/Fas ligand transcription and associated T-cell effector functions. Schwaderer J, etal., Cell Death Dis. 2017 Apr 13;8(4):e2745. doi: 10.1038/cddis.2017.173.
90. MiR-3202 protects smokers from chronic obstructive pulmonary disease through inhibiting FAIM2: An in vivo and in vitro study. Shen W, etal., Exp Cell Res. 2018 Jan 15;362(2):370-377. doi: 10.1016/j.yexcr.2017.11.038. Epub 2017 Dec 5.
91. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Shimonishi T, etal., Hepatology. 2000 Oct;32(4 Pt 1):761-9. doi: 10.1053/jhep.2000.18192.
92. Early detection of apoptosis and fas ligand expression in hepatic graft-versus-host disease after rat small bowel transplantation. Shiraishi M, etal., J Surg Res. 1999 Sep;86(1):136-44. doi: 10.1006/jsre.1999.5706.
93. The many roles of FAS receptor signaling in the immune system. Strasser A, etal., Immunity. 2009 Feb 20;30(2):180-92.
94. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Suda T, etal., Cell 1993 Dec 17;75(6):1169-78.
95. Oxidative stress increases Fas ligand expression in endothelial cells. Suzuki M, etal., J Inflamm (Lond). 2006 Jul 19;3:11.
96. Immunohistochemical study of the apoptosis process in epidermal epithelial cells of rats under a physiological condition. Udayanga KG, etal., Histol Histopathol. 2011 Jul;26(7):811-20. doi: 10.14670/HH-26.811.
97. Apoptosis in the kidneys of patients with type II diabetic nephropathy. Verzola D, etal., Kidney Int. 2007 Nov;72(10):1262-72. Epub 2007 Sep 12.
98. Soluble Fas and Fas-ligand levels in mid-trimester amniotic fluid and their associations with severe small for gestational age fetuses: a prospective observational study. Vrachnis N, etal., J Reprod Immunol. 2013 Jun;98(1-2):39-44. doi: 10.1016/j.jri.2013.02.003. Epub 2013 Apr 10.
99. c-Jun N-terminal kinases mediate Fas-induced neurite regeneration in PC12 cells. Waetzig V, etal., Biochem Pharmacol. 2008 Dec 1;76(11):1476-84. Epub 2008 Jul 19.
100. [Study on expression of Fas/FasL and HBV antigens in liver tissue of patients with hepatitis B]. Wang H, etal., Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2001 Mar;15(1):12-5.
101. Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation. Resistance to Fas ligand-induced apoptosis. Wang W, etal., J Biol Chem 2002 Jun 14;277(24):21723-9.
102. Effects of platelet-derived growth factor and interleukin-10 on Fas/Fas-ligand and Bcl-2/Bax mRNA expression in rat hepatic stellate cells in vitro. Wang XZ, etal., World J Gastroenterol. 2004 Sep 15;10(18):2706-10.
103. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. Wigginton JM, etal., J Clin Invest. 2001 Jul;108(1):51-62.
104. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma. Xu LN, etal., World J Gastroenterol. 2005 Jun 28;11(24):3719-23.
105. Fas- and FasL-deficient mice are resistant to the induction of bleomycin-induced scleroderma. Yamamoto T, etal., Arch Dermatol Res. 2007 Feb;298(9):465-8. Epub 2006 Nov 11.
106. Shenfu Formula reduces cardiomyocyte apoptosis in heart failure rats by regulating microRNAs. Yan X, etal., J Ethnopharmacol. 2018 May 8;227:105-112. doi: 10.1016/j.jep.2018.05.006.
107. Wentong decoction cures allergic bronchial asthma by regulating the apoptosis imbalance of EOS. Yan Y, etal., Chin Med. 2018 Apr 18;13:21. doi: 10.1186/s13020-018-0180-2. eCollection 2018.
108. Functional variants in cell death pathway genes and risk of pancreatic cancer. Yang M, etal., Clin Cancer Res. 2008 May 15;14(10):3230-6.
109. Human neuropathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy. Yu WR, etal., Brain. 2011 May;134(Pt 5):1277-92. doi: 10.1093/brain/awr054. Epub 2011 Apr 13.
110. FAS-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment. Zacks DN, etal., Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4563-9.
111. Association of a CA repeat polymorphism upstream of the Fas ligand gene with multiple sclerosis. Zayas MD, etal., J Neuroimmunol 2001 Jun 1;116(2):238-41.
112. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Zhang B, etal., Carcinogenesis. 2007 May;28(5):1067-73. Epub 2006 Dec 20.
113. Herb-partitioned moxibustion alleviates colon injuries in ulcerative colitis rats. Zhang D, etal., World J Gastroenterol. 2018 Aug 14;24(30):3384-3397. doi: 10.3748/wjg.v24.i30.3384.
114. Intraarticular gene delivery of CTLA4-FasL suppresses experimental arthritis. Zhang W, etal., Int Immunol. 2012 Jun;24(6):379-88. doi: 10.1093/intimm/dxs041. Epub 2012 Feb 21.
115. Fas/FasL-dependent apoptosis of hepatocytes induced in rat and patients with Clonorchis sinensis infection. Zhang X, etal., Parasitol Res. 2008 Jul;103(2):393-9. Epub 2008 Apr 22.
Additional References at PubMed
PMID:7511063   PMID:10588860   PMID:11101870   PMID:12201652   PMID:12477972   PMID:12761501   PMID:14517994   PMID:14576824   PMID:14679192   PMID:14749367   PMID:15039234   PMID:15379972  
PMID:15507796   PMID:15555619   PMID:15629131   PMID:15799720   PMID:16033886   PMID:16226958   PMID:16318909   PMID:16831245   PMID:16921742   PMID:16973387   PMID:17045251   PMID:17053043  
PMID:17076679   PMID:17098047   PMID:17105443   PMID:17241545   PMID:17557115   PMID:17615270   PMID:17658509   PMID:17684774   PMID:18204739   PMID:18246871   PMID:18292530   PMID:18293083  
PMID:18392917   PMID:18726999   PMID:18835034   PMID:19005073   PMID:19239001   PMID:19304523   PMID:19364818   PMID:19407976   PMID:19567205   PMID:20404348   PMID:20406899   PMID:20620473  
PMID:20840605   PMID:21586345   PMID:21625644   PMID:21792649   PMID:22325471   PMID:22609371   PMID:22664023   PMID:22891283   PMID:22892327   PMID:22904205   PMID:22907769   PMID:23711477  
PMID:23806367   PMID:23934924   PMID:23940767   PMID:23949220   PMID:24297385   PMID:24631528   PMID:25294749   PMID:25428397   PMID:25439027   PMID:26519036   PMID:26582200   PMID:26646413  
PMID:27606894   PMID:28722192   PMID:29738767   PMID:29891925   PMID:31416448   PMID:31782491   PMID:33994507   PMID:34296305   PMID:37855249  


Genomics

Comparative Map Data
Faslg
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81376,680,885 - 76,706,042 (-)NCBIGRCr8GRCr8GRCr8
GRCr8 Ensembl1376,688,243 - 76,695,503 (-)EnsemblGRCr8
mRatBN7.21374,151,519 - 74,172,760 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1374,154,954 - 74,162,215 (-)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx1376,724,620 - 76,731,883 (-)NCBIUTH_Rnor_SHR_UtxUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01378,031,667 - 78,038,929 (-)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0UTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01375,291,523 - 75,298,787 (-)NCBIUTH_Rnor_WKY_Bbb_1.0UTH_Rnor_WKY_Bbb_1.0
Rnor_6.01379,696,811 - 79,717,581 (-)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1379,698,445 - 79,705,705 (-)Ensemblrn6Rnor6.0
Rnor_5.01384,590,119 - 84,605,900 (-)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.41377,472,950 - 77,480,210 (-)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera1373,908,438 - 73,915,703 (-)NCBICelera
RGSC_v3.11377,487,137 - 77,494,398 (-)NCBI
Cytogenetic Map13q22NCBI
FASLG
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh381172,659,103 - 172,666,876 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1172,659,102 - 172,666,876 (+)Ensemblhg38GRCh38
GRCh371172,628,243 - 172,636,016 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361170,894,808 - 170,902,636 (+)NCBIBuild 36Build 36hg18NCBI36
Celera1145,737,693 - 145,745,520 (+)NCBICelera
Cytogenetic Map1q24.3NCBI
HuRef1143,852,795 - 143,860,622 (+)NCBIHuRef
CHM1_11174,050,496 - 174,058,323 (+)NCBICHM1_1
T2T-CHM13v2.01172,016,214 - 172,023,987 (+)NCBIT2T-CHM13v2.0
Fasl
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391161,608,260 - 161,616,064 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1161,608,258 - 161,616,064 (-)EnsemblGRCm39 EnsemblGRCm39
GRCm381161,780,691 - 161,788,495 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1161,780,689 - 161,788,495 (-)Ensemblmm10GRCm38
MGSCv371163,710,820 - 163,718,626 (-)NCBIMGSCv37MGSCv37mm9NCBIm37
MGSCv361163,617,366 - 163,625,172 (-)NCBIMGSCv36mm8
Celera1164,235,655 - 164,243,458 (-)NCBICelera
Cytogenetic Map1H2.1NCBI
cM Map169.95NCBI
Faslg
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495540613,098,662 - 13,107,389 (+)Ensembl
ChiLan1.0NW_00495540613,098,479 - 13,107,045 (+)NCBIChiLan1.0ChiLan1.0
FASLG
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v2177,076,483 - 77,084,478 (-)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan1176,756,472 - 76,764,434 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01148,159,826 - 148,167,785 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11151,868,430 - 151,876,281 (+)NCBIPanPan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1151,868,430 - 151,876,281 (+)EnsemblpanPan2panpan1.1
FASLG
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1726,335,837 - 26,344,224 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl726,335,846 - 26,344,224 (-)EnsemblcanFam3CanFam3.1
Dog10K_Boxer_Tasha725,866,683 - 25,875,068 (-)NCBIDog10K_Boxer_TashaDog10K_Boxer_Tasha
ROS_Cfam_1.0726,086,377 - 26,094,750 (-)NCBIROS_Cfam_1.0ROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl726,086,386 - 26,094,750 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1725,997,538 - 26,005,908 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0726,067,461 - 26,075,850 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0726,217,995 - 26,226,386 (-)NCBIUU_Cfam_GSD_1.0UU_Cfam_GSD_1.0
Faslg
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_02440934496,942,494 - 96,949,833 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_00493648114,790,080 - 14,795,780 (-)EnsemblSpeTri2.0 Ensembl
SpeTri2.0NW_00493648114,789,547 - 14,795,780 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
FASLG
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl9115,068,090 - 115,076,464 (+)EnsemblsusScr11Sscrofa11.1
Sscrofa11.19115,068,314 - 115,075,147 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.29126,641,066 - 126,647,827 (-)NCBISscrofa10.2Sscrofa10.2susScr3
FASLG
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.12556,488,572 - 56,496,469 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl2556,489,417 - 56,496,251 (-)EnsemblChlSab1.1 EnsemblchlSab2Vervet-AGM
Vero_WHO_p1.0NW_02366605558,094,483 - 58,102,557 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Faslg
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046247719,032,016 - 9,038,825 (-)EnsemblHetGla_female_1.0 EnsemblhetGla2HetGla_female_1.0 Ensembl
HetGla 1.0NW_0046247719,031,978 - 9,038,760 (-)NCBIHetGla 1.0HetGla 1.0hetGla2
Faslg
(Rattus rattus - black rat)
Black Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Rrattus_CSIRO_v11041,080,568 - 41,093,454 (-)NCBIRrattus_CSIRO_v1

Variants

.
Variants in Faslg
237 total Variants
miRNA Target Status (No longer updated)

Confirmed Target Of
miRNA GeneMature miRNAMethod NameResult TypeData TypeSupport TypePMID
Mir21rno-miR-21-5pMirtarbaseexternal_infoImmunofluorescence//In situ hybridization//LuciferFunctional MTI20840605

Predicted Target Of
Summary Value
Count of predictions:90
Count of miRNA genes:81
Interacting mature miRNAs:85
Transcripts:ENSRNOT00000003998
Prediction methods:Miranda, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (GRCr8)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1298066Bp159Blood pressure QTL 1590.004arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)134863963493639634Rat
10755495Bp387Blood pressure QTL 3873.78arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)133721624190057603Rat
1354655Bp241Blood pressure QTL 2413.9arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1338975045103588154Rat
8655951Rf63Renal function QTL 6312.2blood urea nitrogen amount (VT:0005265)plasma urea nitrogen level (CMO:0000586)1371610804109350286Rat
70220Bp55Blood pressure QTL 555.75arterial blood pressure trait (VT:2000000)blood pressure measurement (CMO:0000003)133992469384924693Rat
8655945Rf61Renal function QTL 613.6blood creatinine amount (VT:0005328)creatinine clearance (CMO:0000765)137161080489333251Rat
71119Thym2Thymus enlargement QTL 23.8thymus mass (VT:0004954)thymus weight to body weight ratio (CMO:0000612)134874981487285480Rat
4889861Pur29Proteinuria QTL 2913.80.005urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)133996821183286298Rat
1331783Bp221Blood pressure QTL 2213.72886arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)137161080489333251Rat
8655959Pur32Proteinuria QTL 328.4urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)137298450699745408Rat
2293687Bss26Bone structure and strength QTL 264.60.0001femur morphology trait (VT:0000559)femur cross-sectional area (CMO:0001661)1367635937109350286Rat
1300166Kidm6Kidney mass QTL 63.93kidney mass (VT:0002707)single kidney wet weight to body weight ratio (CMO:0000622)137161080489333251Rat
619615Bp80Blood pressure QTL 800.0354arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)13742179187286911Rat
61340Bp25Blood pressure QTL 254.20.004arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)133708798382087983Rat
1581573Uae36Urinary albumin excretion QTL 36urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)13600200888706694Rat
1549897Stresp12Stress response QTL 123.35stress-related behavior trait (VT:0010451)number of approaches toward negative stimulus before onset of defensive burying response (CMO:0001960)134098358585983585Rat
724564Uae11Urinary albumin excretion QTL 115.7urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)134735425894285672Rat
7207885Glom27Glomerulus QTL 273.9kidney glomerulus integrity trait (VT:0010546)kidney crescentic glomeruli count to kidney normal glomeruli count ratio (CMO:0002139)1321120177109350286Rat
738027Lnnr6Liver neoplastic nodule remodeling QTL 63.3liver integrity trait (VT:0010547)liver remodeling tumorous lesion number (CMO:0001461)1365613454109350286Rat
7387280Uae43Urinary albumin excretion QTL 435.690.4174urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1368983334109350286Rat
738026Lnnr5Liver neoplastic nodule remodeling QTL 53.29liver integrity trait (VT:0010547)liver remodeling tumorous lesion number (CMO:0001461)136242459288113509Rat
70181BpQTLcluster11Blood pressure QTL cluster 116.922arterial blood pressure trait (VT:2000000)absolute change in mean arterial blood pressure (CMO:0000533)133379409678794096Rat
2293702Bss34Bone structure and strength QTL 344.610.0001femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)1367635937109350286Rat
61349Bp31Blood pressure QTL 315.75arterial blood pressure trait (VT:2000000)blood pressure measurement (CMO:0000003)133992469384924693Rat
1576318Schws5Schwannoma susceptibility QTL 50.0351nervous system integrity trait (VT:0010566)post-insult time to trigeminal nerve neurilemmoma formation (CMO:0002019)1364497900109350286Rat
2303563Bw89Body weight QTL 896body mass (VT:0001259)body weight (CMO:0000012)133483494779834947Rat
1354621Rf47Renal function QTL 473.7kidney renin amount (VT:0010559)kidney renin level (CMO:0002166)1311081740103588154Rat
1581554Pur11Proteinuria QTL 11urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)13600200888706694Rat
12879477Bp401Blood pressure QTL 401arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)133981472684814726Rat
1331750Bp220Blood pressure QTL 2202.98arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)133996821184968211Rat
12879475Bp400Blood pressure QTL 400arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1364375743109350286Rat
11530006Niddm72Non-insulin dependent diabetes mellitus QTL 720.001blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)133828629883286298Rat
1354666Bp244Blood pressure QTL 2444.9arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)131103588154Rat
2293341Glom15Glomerulus QTL 159.1kidney glomerulus integrity trait (VT:0010546)kidney sclerotic glomeruli count to total glomeruli count ratio (CMO:0001269)1367635937109350286Rat


Genetic Models
This gene Faslg is modified in the following models/strains:
F344-FaslgTn(sb-T2/Bart3)2.325Mcwi    


Expression

RNA-SEQ Expression

alimentary part of gastrointestinal system
appendage
circulatory system
ectoderm
endocrine system
endoderm
exocrine system
hemolymphoid system
hepatobiliary system
integumental system
mesenchyme
mesoderm
musculoskeletal system
nervous system
renal system
reproductive system
respiratory system
sensory system
visual system
16 9 64 160 90 89 58 92 58 6 343 182 11 139 79 91 31 13 13

Sequence


Ensembl Acc Id: ENSRNOT00000003998   ⟹   ENSRNOP00000003998
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8 Ensembl1376,688,243 - 76,695,503 (-)Ensembl
mRatBN7.2 Ensembl1374,154,954 - 74,162,215 (-)Ensembl
Rnor_6.0 Ensembl1379,698,445 - 79,705,705 (-)Ensembl
RefSeq Acc Id: NM_012908   ⟹   NP_037040
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81376,688,243 - 76,695,503 (-)NCBI
mRatBN7.21374,154,954 - 74,162,215 (-)NCBI
Rnor_6.01379,698,445 - 79,705,705 (-)NCBI
Rnor_5.01384,590,119 - 84,605,900 (-)NCBI
RGSC_v3.41377,472,950 - 77,480,210 (-)RGD
Celera1373,908,438 - 73,915,703 (-)RGD
Sequence:
RefSeq Acc Id: XM_017598675   ⟹   XP_017454164
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81376,680,885 - 76,706,042 (-)NCBI
mRatBN7.21374,151,519 - 74,172,760 (-)NCBI
Rnor_6.01379,696,811 - 79,716,392 (-)NCBI
Sequence:
Protein Sequences
Protein RefSeqs NP_037040 (Get FASTA)   NCBI Sequence Viewer  
  XP_017454164 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein AAC52129 (Get FASTA)   NCBI Sequence Viewer  
  CTQ86170 (Get FASTA)   NCBI Sequence Viewer  
  EDM09413 (Get FASTA)   NCBI Sequence Viewer  
Ensembl Protein ENSRNOP00000003998
  ENSRNOP00000003998.2
GenBank Protein P36940 (Get FASTA)   NCBI Sequence Viewer  
RefSeq Acc Id: NP_037040   ⟸   NM_012908
- UniProtKB: P36940 (UniProtKB/Swiss-Prot),   A0A0U5J7X8 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_017454164   ⟸   XM_017598675
- Peptide Label: isoform X1
- UniProtKB: P36940 (UniProtKB/Swiss-Prot),   A0A0U5J7X8 (UniProtKB/TrEMBL)
- Sequence:
Ensembl Acc Id: ENSRNOP00000003998   ⟸   ENSRNOT00000003998
Protein Domains
THD

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P36940-F1-model_v2 AlphaFold P36940 1-278 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen


Additional Information

Database Acc Id Source(s)
AGR Gene RGD:3880 AgrOrtholog
BioCyc Gene G2FUF-17702 BioCyc
Ensembl Genes ENSRNOG00000002978 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000003998 ENTREZGENE
  ENSRNOT00000003998.3 UniProtKB/Swiss-Prot
Gene3D-CATH 2.60.120.40 UniProtKB/Swiss-Prot
InterPro FASL UniProtKB/Swiss-Prot
  TNF_CS UniProtKB/Swiss-Prot
  TNF_dom UniProtKB/Swiss-Prot
  Tumour_necrosis_fac-like_dom UniProtKB/Swiss-Prot
KEGG Report rno:25385 UniProtKB/Swiss-Prot
NCBI Gene 25385 ENTREZGENE
PANTHER TUMOR NECROSIS FACTOR FAMILY MEMBER UniProtKB/Swiss-Prot
  TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 6 UniProtKB/Swiss-Prot
Pfam TNF UniProtKB/Swiss-Prot
PhenoGen Faslg PhenoGen
PRINTS FASLIGAND UniProtKB/Swiss-Prot
PROSITE TNF_1 UniProtKB/Swiss-Prot
  TNF_2 UniProtKB/Swiss-Prot
RatGTEx ENSRNOG00000002978 RatGTEx
SMART TNF UniProtKB/Swiss-Prot
Superfamily-SCOP SSF49842 UniProtKB/Swiss-Prot
UniProt A0A0U5J7X8 ENTREZGENE, UniProtKB/TrEMBL
  P36940 ENTREZGENE, UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2008-09-25 Faslg  Fas ligand (TNF superfamily, member 6)  Fasl  Fas ligand (TNF superfamily, member 6)  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-02-15 Fasl  Fas ligand (TNF superfamily, member 6)  Faslg  Fas ligand (TNF superfamily, member 6)  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2006-03-30 Faslg  Fas ligand (TNF superfamily, member 6)  Tnfsf6  tumor necrosis factor (ligand) superfamily, member 6  Symbol and Name updated 1299863 APPROVED
2002-06-10 Tnfsf6  tumor necrosis factor (ligand) superfamily, member 6      Name updated 70584 APPROVED
2002-02-06 Fasl  Fas antigen ligand      Fasl withdrawn and merged with Tnfsf6 (RGD:3880) 68913 WITHDRAWN
2001-06-22 Tnfsf6  Tumor necrosis factor (ligand) superfamily, member 6      Name updated, removed withdrawn gene name text 67952 APPROVED
2001-06-22 Apt1Lg1  Apoptosis (APO-1) antigen ligand 1 (Fas antigen ligand)      Symbol withdrawn, duplicate of Tnfsf6 (RGD:3880) 67952 WITHDRAWN

RGD Curation Notes
Note Type Note Reference
gene_regulation mRNA expression increases in response to hydrogen peroxide 730260